FDA Opens the U.S. to In Vivo Prime Editing

Company Prime Medicine Event Type Regulatory Clearance (FDA IND) / Clinical Trial Initiation (Phase 1/2) Modality In Vivo Prime Editing (LNP-Delivered) Asset PM577a Target ATP7B (H1069Q mutation) Disease Area Wilson Disease Summary The U.S. FDA cleared Prime Medicine’s investigational new drug application for PM577a, an…